Flag of the European Union EU Clinical Trials Register Help

Clinical trials for SU011248 (Sunitinib)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    41 result(s) found for: SU011248 (Sunitinib). Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2005-005335-94 Sponsor Protocol Number: A6181078 Start Date*: 2006-03-21
    Sponsor Name:Pfizer, S.A.
    Full Title: A TREATMENT PROTOCOL FOR PATIENTS CONTINUING FROM A PRIOR SU011248 PROTOCOL Protocolo de continuación de tratamiento para pacientes provenientes de un protocolo previo con SU011248
    Medical condition: Patients with any malignancy who have previously been evaluated in a SU001248 protocol
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Completed) NL (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001303-19 Sponsor Protocol Number: A6181047 Start Date*: 2005-10-18
    Sponsor Name:PFIZER
    Full Title: A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 ADMINISTERED IN A CONTINUOUS DAILY REGIMEN IN PATIENTS WITH ADVANCED GASTRO INTESTINAL STROMAL TUMOR
    Medical condition: Imatinib mesylate-resistant malignant gastrointestinal stromal tumor
    Disease: Version SOC Term Classification Code Term Level
    6.1 10053548 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002097-30 Sponsor Protocol Number: A6181037 Start Date*: 2005-10-12
    Sponsor Name:PFIZER Inc 235 East 42nd Street, New York, NY, 10017
    Full Title: A SU011248 EXPANDED ACCESS PROTOCOL FOR SYSTEMIC THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS BUT MAY DERIVE BENEFIT FRO...
    Medical condition: Histopathologically confirmed renal cell carcinoma with metastases
    Disease: Version SOC Term Classification Code Term Level
    8.0 10038415 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SK (Completed) HU (Completed) SE (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) SI (Completed) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000690-23 Sponsor Protocol Number: ADVL0612;NCI-07-C-0220 Start Date*: 2012-02-29
    Sponsor Name:National Institution of Health (NCI)
    Full Title: A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors
    Medical condition: Paediatric solid tumours
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-002008-33 Sponsor Protocol Number: A6181196 Start Date*: 2012-02-21
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR
    Medical condition: Pediatric Gastro Intestinal Stromal Tumor (GIST)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) Outside EU/EEA CZ (Completed) PT (Completed) IT (Completed) GB (Completed) PL (Completed) AT (Completed) DE (Completed) FR (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2005-000524-16 Sponsor Protocol Number: A6181054 Start Date*: 2006-01-12
    Sponsor Name:Laboratorios Pfizer, Lda
    Full Title: AN OPEN LABEL INTERNATIONAL MULTI-CENTER PHASE 2 ACTIVITY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH ADVANCED / METASTATIC GASTRIC CANCER PROGRESSING OR RECURRING AFTER ONE PRIOR CHEMOTHERAPY
    Medical condition: Histologically or cytologically confirmed diagnosis of gastric adenocarcinoma or gastroesophageal junction adenocarcinoma (i.e. an adenocarcinoma with >50% extension in the stomach). Patients must...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10017758 LLY
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002987-84 Sponsor Protocol Number: A6181104 Start Date*: 2008-07-31
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, NEW YORK, NY 10017. US
    Full Title: A RANDOMIZED, PHASE 2B STUDY OF SUNITINIB PLUS OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFOX) VERSUS BEVACIZUMAB PLUS FOLFOX AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Medical condition: METASTATIC COLORECTAL CANCER
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-006459-38 Sponsor Protocol Number: Iridium 07 01 Start Date*: 2008-08-29
    Sponsor Name:St Augustinus
    Full Title: CONTINUOUS TREATMENT WITH SUNITINIB IN PATIENTS WITH SYMPTOMATIC PLEURAL AND/OR PERITONEAL MALIGNANT EFFUSIONS.
    Medical condition: Symtomatic malignant pleural and/ or peritoneal effusions regardless of the primary tumor site or histological charestistics
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001149-14 Sponsor Protocol Number: A6181034 Start Date*: 2004-09-27
    Sponsor Name:PFIZER
    Full Title: A Phase 3, Randomized Study of SU011248 versus Interferon-a as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma.
    Medical condition: metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10050513 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000476-33 Sponsor Protocol Number: GC-SU-2006 Start Date*: 2006-11-20
    Sponsor Name:Johannes-Gutenberg-Universität Mainz, I. Medizinische Klinik und Poliklinik
    Full Title: An open-label, multicenter phase II trial of Sunitinib for patients with chemo-refractory metastatic gastric cancer
    Medical condition: Chemorefractory metastatic adenocarcinoma of stomach, esophagogastric junction and lower esophagus (Barrett carcinoma)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017758 Gastric cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001093-11 Sponsor Protocol Number: A6181030 Start Date*: 2004-12-24
    Sponsor Name:Pfizer Global Research and Development
    Full Title: A Treatment Protocol for Patients Continuing from a Prior SU011248 Protocol
    Medical condition: This is an open-label treatment protocol for patients who have participated in other SU011248 protocols to completion and are believed to have the potential to derive clinical benefit from SU011248...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10062427 LLY
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) NL (Completed) SE (Completed) GR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000526-23 Sponsor Protocol Number: A6181049 Start Date*: 2005-08-30
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 1 STUDY OF SU011248 IN COMBINATION WITH FOLFIRI (IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN) IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Medical condition: Metastatic colorectal cancer.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006538-16 Sponsor Protocol Number: A6181114 Start Date*: 2007-03-30
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017, US
    Full Title: AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNI...
    Medical condition: Malignant Gastrointestinal Stromal Tumor (GIST), Metastatic Breast Cancer, Metastatic Renal Cell Cancer, Pancreatic Neuroendocrine Tumor, Hepatocellular Carcinoma, Prostate Cancer, Thyroid Cancer, ...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027655 Miscellaneous and site unspecified neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FR (Completed) DK (Prematurely Ended) GB (Completed) NL (Prematurely Ended) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-001780-30 Sponsor Protocol Number: GORTEC 2006-01 Start Date*: 2007-02-28
    Sponsor Name:UCL Saint Luc 1200 Bruxelles
    Full Title: Etude de phase III du SU011248 chez les patients atteints d'un cancer épidermoïde de la tête et du cou en situation de rechute locorégionale et/ou métastatique
    Medical condition: Cet essai s'adresse à des patients porteurs d'un carcinome épidermoïde de la tête et du cou en rechute locale ou en situation métastatique et qui ne peuvent plus bénéficier d'un traitement curatif
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002240-14 Sponsor Protocol Number: TARIBO Start Date*: 2015-09-29
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Targeted Therapy with or without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery
    Medical condition: Patients affected by non treated metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073251 Clear cell renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001165-15 Sponsor Protocol Number: SIRAC-1 Start Date*: 2007-06-08
    Sponsor Name:University Hospital of Wuerzburg
    Full Title: Sunitinib in Refractory Adrenocortical-Carcinoma patients progressing after cytotoxic chemotherapy (SIRAC)
    Medical condition: Adrenocortical Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001388 Adrenocortical carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005033-29 Sponsor Protocol Number: CT/08.22 Start Date*: 2009-07-20
    Sponsor Name:Vassilis Georgoulias, Prof. of Internal Medicine-Oncology of Medical Dpt University of Crete
    Full Title: A PHASE II STUDY OF sunitinib IN PATIENTS WITH ADVANCED HORMONE RESISTANT AND CHEMOTHERAPY RESISTANT PROSTATE CANCER.
    Medical condition: Patients with advanced hormone resistant and chemotherapy resistant prostate cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003773-25 Sponsor Protocol Number: A6181067 Start Date*: 2006-01-03
    Sponsor Name:PFIZER S.A
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF SU011248 IN COMBINATION WITH TRASTUZUMAB AS FIRST-LINE TREATMENT FOR METASTATIC DISEASE IN PATIENTS WITH BREAST CANCER
    Medical condition: Histologically or cytologically proven diagnosis of breast cancer with evidence of 1) unresectable, locally recurrent, or 2) metastatic disease. Locally recurrent disease must not be amenable to r...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10055113 LLY
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004363-74 Sponsor Protocol Number: A6181202 Start Date*: 2012-02-02
    Sponsor Name:Pfizer Inc.
    Full Title: A SINGLE ARM OPEN LABEL INTERNATIONAL MULTI CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT®) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL DIFFERENTIATED UNRE...
    Medical condition: PROGRESSIVE ADVANCED METASTATIC WELL DIFFERENTIATED UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) HU (Completed) ES (Completed) BE (Completed) PT (Completed) PL (Completed) SK (Completed) EE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005115-16 Sponsor Protocol Number: SU-011248 Start Date*: 2006-05-05
    Sponsor Name:Joaquim Bellmunt Molins
    Full Title: A phase ii study assesing su-011248 in previously untreated patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy Estudio fase II que evalúa la eficacia y tolerabilid...
    Medical condition: Previously untreated patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Aug 06 08:27:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA